ABNewswire - Press Release Distribution Service

Wednesday, March 11, 2026

Multiple Sclerosis Pipeline Expands with 80+ Drugs and 75+ Companies Advancing Next-Generation Therapies | DelveInsight

Multiple Sclerosis Pipeline

Multiple Sclerosis companies include Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., ImCyse, and others.

DelveInsight’s “Multiple Sclerosis Pipeline Insight 2026” report delivers detailed intelligence on more than 75 organizations and over 80 investigational therapies within the multiple sclerosis development pipeline. The report evaluates drug profiles across both clinical and preclinical stages. It also assesses therapeutic candidates based on product category, development phase, route of administration, and molecular classification. Additionally, the study outlines discontinued or inactive pipeline assets in this therapeutic area.

Explore the newest therapies and emerging treatment opportunities within the Multiple Sclerosis pipeline. Access DelveInsight’s comprehensive research report today! @ Multiple Sclerosis Pipeline Outlook @ https://www.delveinsight.com/report-store/multiple-sclerosis-pipeline-insight

Key Highlights from the Multiple Sclerosis Pipeline Report

January 20, 2026: The National Institute of Allergy and Infectious Diseases (NIAID) initiated a prospective, multicenter, randomized, double-blind, placebo-controlled study evaluating the discontinuation of OCR therapy in individuals with early relapsing multiple sclerosis (RMS). Eligible participants will begin OCR treatment following the approved dosing schedule—two 300 mg infusions separated by 14 days (Day 0 and Day 14) totaling 600 mg, followed by 600 mg infusions at Months 6, 12, 18, and 24. At Month 24, patients will be randomized in a 2:1 ratio into two groups beginning treatment at Month 30:

Arm 1: placebo infusion every six months
Arm 2: OCR infusion every six months

The study’s treatment duration will extend for 48 months.

January 16, 2026: Sanofi announced a clinical trial aimed at assessing the efficacy of frexalimab in delaying disability progression and evaluating safety during 36 months of double-blind treatment compared with placebo. The trial includes male and female patients aged 18–60 diagnosed with non-relapsing secondary progressive multiple sclerosis (nrSPMS) who meet the defined eligibility criteria.

January 08, 2026: Hoffmann-La Roche launched a clinical study to examine the bioequivalence of a subcutaneous (SC) test formulation of ocrelizumab compared with the marketed reference formulation in patients with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). The study includes two phases:

Controlled phase: Participants receive either the test or reference formulation.
Continuation phase: All participants receive the test formulation of ocrelizumab SC.

According to DelveInsight’s analysis, the Multiple Sclerosis therapeutic pipeline remains highly active, with over 75 pharmaceutical and biotech companies advancing more than 80 innovative therapies aimed at improving treatment outcomes.

Prominent companies involved in the Multiple Sclerosis drug development space include Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., ImCyse, and others.

Notable investigational and approved therapies shaping the pipeline include 11C-BMS-986196, ofatumumab, Fingolimod, Siponimod, elezanumab, Alemtuzumab, Tecfidera, and several other candidates.

Stay updated with the latest developments in Multiple Sclerosis therapeutics. Gain insights into clinical studies, novel drugs, and key pharmaceutical players through DelveInsight’s analysis @ Multiple Sclerosis Treatment Drugs @ https://www.delveinsight.com/report-store/multiple-sclerosis-pipeline-insight

Overview of the Multiple Sclerosis Pipeline Report

The Multiple Sclerosis Pipeline Insight report offers a detailed review of the disease background, ongoing research activities, and therapeutic evaluation of key drug candidates currently under development. The report also identifies major unmet medical needs and areas where innovation is required to improve treatment options for patients with Multiple Sclerosis.

Multiple Sclerosis: Disease Overview

Multiple Sclerosis (MS) is one of the most prevalent neurological disorders affecting young adults, with initial symptoms commonly appearing between 20 and 40 years of age. The disease targets the axons of the central nervous system, which are protected by myelin (white matter). Damage to this protective layer disrupts nerve signaling and leads to a range of neurological symptoms.

The most common form of the disease is Relapsing–Remitting Multiple Sclerosis (RRMS), accounting for approximately 85% of MS cases. RRMS is characterized by periodic relapses or flare-ups, followed by phases of remission, during which symptoms partially or completely subside.

Emerging Drug Profiles for Multiple Sclerosis

IMU-838: Immunic Therapeutics

Vidofludimus calcium (IMU-838) is an investigational small-molecule therapy being developed as an oral tablet for treating relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease, and other autoimmune disorders. Encouraging results from the Phase II EMPhASIS clinical trial indicate the drug may offer significant therapeutic advantages, particularly in early-stage RMS patients. The therapy demonstrates a placebo-like safety profile combined with strong anti-inflammatory and neuroprotective effects, supporting its potential as a promising treatment option.

BIIB091: Biogen

BIIB091 is designed to selectively inhibit Bruton’s tyrosine kinase (BTK), a non-receptor enzyme involved in regulating B-cell and myeloid cell signaling, both of which play roles in the pathogenesis of MS. BTK also influences Fc gamma receptor signaling, which activates myeloid immune cells. Preclinical studies show that BIIB091 exhibits high potency, favorable drug-like characteristics, and a promising safety profile, supporting its development as a reversible and selective BTK inhibitor for autoimmune diseases such as MS. The therapy is currently undergoing Phase II clinical evaluation.

IMCY-0141: ImCyse

IMCY-0141 represents the second clinical-stage candidate from ImCyse. This Imotope-based therapy is engineered from myelin oligodendrocyte glycoprotein (MOG) and is designed to halt MS progression by preventing the immune system from attacking the central nervous system. Preclinical studies have demonstrated promising immune responses, supporting its proposed mechanism of action and suggesting long-lasting therapeutic effects with less frequent dosing. Early intervention with this therapy may enable patients to experience minimal disease burden. The candidate is currently being studied in Phase I/II clinical trials.

CC-97540: Bristol-Myers Squibb

CC-97540 is an experimental therapy from Bristol-Myers Squibb developed as a selective oral inhibitor of tyrosine kinase 2 (TYK2). TYK2 plays a critical role in the signaling pathways of pro-inflammatory cytokines such as IL-12, IL-23, and type I interferons, which are involved in autoimmune and inflammatory diseases. By specifically targeting TYK2 while avoiding significant inhibition of other JAK family enzymes, the drug may reduce inflammation with fewer adverse effects compared to broader JAK inhibitors. Although it is also being studied for conditions such as psoriasis and systemic lupus erythematosus, the therapy is currently in Phase I trials for Multiple Sclerosis.

Explore innovative therapeutic strategies and clinical research shaping the Multiple Sclerosis treatment landscape. Access DelveInsight’s full report today! @ New Multiple Sclerosis Drugs @ https://www.delveinsight.com/report-store/multiple-sclerosis-pipeline-insight

Insights Offered in the Multiple Sclerosis Pipeline Report

The report provides in-depth insights into pharmaceutical and biotechnology companies working on therapies for Multiple Sclerosis, along with the number of candidates developed by each organization.

It categorizes therapeutic candidates across early-stage, mid-stage, and late-stage clinical development, offering a comprehensive view of ongoing research efforts.

The report also identifies active, dormant, and discontinued drug development programs, providing a complete understanding of the pipeline dynamics.

Additionally, the report evaluates pipeline drugs based on several parameters including:

Stage of development
Route of administration
Target receptor
Monotherapy vs. combination therapy
Mechanism of action
Molecular type

It also includes detailed analysis of collaborations, licensing agreements, and funding activities, including company-to-company and academia partnerships, which support the advancement of new MS treatments.

Leading Companies in the Multiple Sclerosis Pipeline

Key players involved in developing Multiple Sclerosis treatments include Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., and ImCyse, among others.

Route of Administration Categories

Pipeline therapies for Multiple Sclerosis are being developed across several routes of administration, including:

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Molecule Types Under Development

The report also categorizes MS pipeline drugs by molecular type, including:

Recombinant fusion proteins
Small molecules
Monoclonal antibodies
Peptides
Polymers
Gene therapies

Discover the future outlook for Multiple Sclerosis treatments. Learn about emerging drugs, innovative therapies, and leading industry participants through DelveInsight’s expert analysis @ Multiple Sclerosis Market Drivers and Barriers - @ https://www.delveinsight.com/sample-request/multiple-sclerosis-pipeline-insight

Scope of the Multiple Sclerosis Pipeline Report

Coverage: Global
Key Companies: Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., ImCyse, and others.
Key Therapies: 11C-BMS-986196, ofatumumab, Fingolimod, Siponimod, elezanumab, Alemtuzumab, Tecfidera, and additional candidates.
Therapeutic Assessment by Product Type: Monotherapy, Combination Therapy, Mono/Combination
Clinical Development Stages Covered: Discovery, Preclinical, Phase I, Phase II, Phase III

Access the latest insights on Multiple Sclerosis therapies and ongoing clinical trials. Download DelveInsight’s comprehensive pipeline analysis today! @ Multiple Sclerosis Companies, Key Products and Unmet Needs @ https://www.delveinsight.com/sample-request/multiple-sclerosis-pipeline-insight

About DelveInsight

DelveInsight is a leading healthcare market research and consulting organization dedicated to delivering high-quality market intelligence and strategic insights that support informed business decisions. With a team of experienced analysts and deep expertise in the life sciences and healthcare sectors, the company provides customized research solutions and actionable insights to clients worldwide. Connect with DelveInsight to access accurate, timely, and strategic intelligence that helps organizations stay ahead in a rapidly evolving healthcare landscape.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Autosomal Dominant Polycystic Kidney Disease Market Set for Robust Growth by 2034 Amid Advancing Therapeutics Landscape | DelveInsight

The dynamics of the autosomal dominant polycystic kidney disease market are anticipated to change in the coming years, owing to the launch of emerging therapies such as XRx-008 (Xortx Therapeutics), CYX082 (Novartis), AZD1613 (AstraZeneca), VX-407 (Vertex Pharmaceuticals), ABBV-CLS-628 (Calico Life Sciences/AbbVie), and others and increasing cases of ADPKD during the forecast period (2025–2034).

Recently published Autosomal Dominant Polycystic Kidney Disease Market Insights report includes a comprehensive understanding of current treatment practices, autosomal dominant polycystic kidney disease emerging drugs, market share of autosomal dominant polycystic kidney diseaseindividual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Autosomal Dominant Polycystic Kidney Disease Market Summary

In 2024, the total market size for ADPKD in the 7MM was approximately USD 1.4 billion, and it is expected to grow significantly by 2034.

The US accounted for the highest market size of ADPKD in 2024, i.e., 66%, in comparison to EU4 (Germany, Italy, France, and Spain), the UK, and Japan.

The total diagnosed prevalent cases of ADPKD in the 7MM were found to be approximately 371K in 2024.
Leading autosomal dominant polycystic kidney disease companies, such as Xortx Therapeutics, Novartis, AstraZeneca, Vertex Pharmaceuticals, Calico Life Sciences, and others, are developing new ADPKD treatment drugs that can be available in the ADPKD market in the coming years.
The promising ADPKD therapies in clinical trials include XRx-008, CYX082, AZD1613, VX-407, ABBV-CLS-628, and others.

Download report on global ADPKD market valuation and projection to 2034 @ https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market

Key Factors Driving the Growth of the ADPKD Market

Rising Prevalence of ADPKD: The increasing prevalence of ADPKD worldwide is a major factor driving market growth. As per the estimates, the US accounted for approximately 145K diagnosed prevalent cases of ADPKD in 2024. These cases are expected to increase during the forecast period (2025-2034) due to the aging population, advancements in genetic testing, and diagnostic tools.
Advancements in Diagnostic Technologies: Technological advances in diagnostic procedures due to an increasing focus on early diagnosis have reduced undiagnosed cases, thus persistently rising cases of diagnosed ADPKD offer opportunities to companies to launch new therapies in the market.
Role of Biomarkers in Early Risk Stratification of ADPKD: Identification of biomarkers for early detection of ADPKD patients at high risk for progression will help better manage ADPKD patients and prevent their progression.
Introduction of Disease-Modifying Therapies: The dynamics of the ADPKD market are expected to change in the coming years due to the launch of emerging therapies such as XRx-008 (Xortx Therapeutics), CYX082 (Novartis), AZD1613 (AstraZeneca), VX-407 (Vertex Pharmaceuticals), ABBV-CLS-628 (Calico Life Sciences), and others.

Autosomal Dominant Polycystic Kidney Disease Market Analysis

Currently, there is no definitive cure for ADPKD. Most existing treatment strategies are aimed at managing disease-related complications, slowing the decline in kidney function, and reducing the rate of cyst growth.
For patients with hypertension associated with ADPKD, specialists commonly prescribe angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs).
In these patients, such medications may offer greater benefits in maintaining kidney function and lowering the risk of left ventricular hypertrophy compared with other antihypertensive treatments.
At present, JYNARQUE/JINARC (tolvaptan), developed by Otsuka Pharmaceutical, is the only therapy approved by the U.S. Food and Drug Administration for adults with rapidly progressing ADPKD.
However, its use is limited by a restricted distribution program because of several contraindications, and it carries a boxed warning for patients with cirrhosis or impaired liver function.
Concerns related to its safety and effectiveness across diverse patient populations, along with uncertainty regarding its ability to significantly reduce the need for kidney transplantation, remain challenges.
Additionally, the high cost of treatment adds further complexity to its accessibility and adoption.
The pipeline of emerging treatments for ADPKD shows promise, with mid-late stage products such as Xortx Therapeutics' XRx-008, Novartis’ CYX082, AstraZeneca’s AZD1613, Vertex Pharmaceuticals’ VX-407, Calico Life Sciences’ ABBV-CLS-628, and others, demonstrating the potential to significantly impact the market and potentially revolutionize the treatment approach for ADPKD.

Autosomal Dominant Polycystic Kidney Disease Competitive Landscape

Some of the ADPKD drugs under development include XRx-008 (Xortx Therapeutics), CYX082 (Novartis), AZD1613 (AstraZeneca), VX-407 (Vertex Pharmaceuticals), ABBV-CLS-628 (Calico Life Sciences), and others.

Xortx Therapeutics’ XRx-008 is a proprietary formulation of oxypurinol developed by Xortx under its granted formulation patent. It is designed for once-daily administration to reduce uric acid production by inhibiting xanthine oxidase, which may help limit chronic kidney damage associated with the progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Recently, Xortx reported positive topline results from the XRX-OXY-101 bridging study, which aimed to evaluate the safety profile and relative bioavailability of the XRx-008 formulation. The candidate may follow the FDA 505(b)(2) pathway, enabling development of a reformulated version of oxypurinol with improved bioavailability and better tolerability compared with Allopurinol, potentially supporting regulatory approval.

Novartis’ CYX082, on the other hand, is a next-generation oligonucleotide therapy being developed for ADPKD that is designed to inhibit miR-17 while preferentially targeting the kidney. In preclinical studies, treatment with CYX082 has demonstrated strong efficacy, including improvements in kidney function, reductions in kidney size, and better overall indicators of disease severity. It has also shown a more favorable pharmacologic profile compared with the first-generation compound developed by Regulus Therapeutics.

The anticipated launch of these emerging therapies are poised to transform the ADPKD market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the ADPKD market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about ADPKD pipeline drugs and clinical stages @ Autosomal Dominant Polycystic Kidney Disease Drugs Market

Recent Developments in the Autosomal Dominant Polycystic Kidney Disease Market

In November 2025, Renasant Bio announced that it had launched to drive the development of next-generation treatments targeting autosomal dominant polycystic kidney disease (ADPKD), a major inherited cause of end-stage renal failure.
In November 2025, Calico Life Sciences LLC revealed that the FDA had granted Orphan Drug Designation to ABBV-CLS-628, a potential therapy aimed at treating ADPKD.
In October 2025, Calico Life Sciences LLC announced that ABBV-CLS-628, a potential therapy for ADPKD, had received Fast Track Designation from the FDA.
In March 2025, Regulus Therapeutics announced the successful completion of its Phase 1b Multiple-Ascending Dose(MAD) clinical trial of Farabursen (RGLS8429), a treatment candidate for ADPKD.

What is Autosomal Dominant Polycystic Kidney Disease?

Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a common inherited kidney disorder characterized by the progressive development of numerous fluid-filled cysts in the kidneys. These cysts gradually enlarge over time, causing the kidneys to increase in size and lose their ability to function properly. ADPKD is primarily caused by mutations in the PKD1 or PKD2 genes and follows an autosomal dominant inheritance pattern, meaning a person only needs to inherit one copy of the mutated gene from a parent to develop the condition. The disease typically manifests in adulthood and may lead to symptoms such as high blood pressure, flank pain, blood in the urine, kidney stones, and progressive kidney failure. Over time, many patients with ADPKD may develop complications, including chronic kidney disease and end-stage renal disease, often requiring dialysis or kidney transplantation for management.

Autosomal Dominant Polycystic Kidney Disease Epidemiology Segmentation

The ADPKD epidemiology section provides insights into the historical and current ADPKD patient pool and forecasted trends for the leading markets. The ADPKD treatment market reportproffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:

Total diagnosed Prevalent Cases of ADPKD
Age-specific Diagnosed Prevalent Cases of ADPKD
Mutation-specific Diagnosed Prevalent Cases of ADPKD
Total Treated Cases of ADPKD

Autosomal Dominant Polycystic Kidney Disease Market Forecast Report Metrics

Study Period: 2020–2034
Coverage: 7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Autosomal Dominant Polycystic Kidney Disease Epidemiology Segmentation: Total diagnosed Prevalent Cases of ADPKD, Age-specific Diagnosed Prevalent Cases of ADPKD, Mutation-specific Diagnosed Prevalent Cases of ADPKD, and Total Treated Cases of ADPKD
Autosomal Dominant Polycystic Kidney Disease Market Size in 2024: USD 1.4 Billion
Key Autosomal Dominant Polycystic Kidney Disease Companies: Xortx Therapeutics, Novartis, AstraZeneca, Vertex Pharmaceuticals, Calico Life Sciences, Otsuka Pharmaceutical, and others
Key Autosomal Dominant Polycystic Kidney Disease Therapies: XRx-008, CYX082, AZD1613, VX-407, ABBV-CLS-628, JYNARQUE/JINARC, and others

Scope of the Autosomal Dominant Polycystic Kidney Disease Market Report

Therapeutic Assessment: Autosomal Dominant Polycystic Kidney Disease current marketed and emerging therapies
Autosomal Dominant Polycystic Kidney Disease Market Dynamics: Key Market Forecast Assumptions of Emerging Autosomal Dominant Polycystic Kidney Disease Drugs and Market Outlook
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL’s views, Analyst’s views, Autosomal Dominant Polycystic Kidney Disease Market Access and Reimbursement

Download the report to understand factors driving ADPKD market growth @Autosomal Dominant Polycystic Kidney Disease Market Forecast

Table of Contents

1. Autosomal Dominant Polycystic Kidney Disease Market Key Insights

2. Autosomal Dominant Polycystic Kidney Disease Market Report Introduction

3. Executive Summary

4. Key Events

5. Epidemiology and Market Forecast Methodology

6. Autosomal Dominant Polycystic Kidney Disease Market Overview at a Glance

7. Disease Overview: Autosomal Dominant Polycystic Kidney Disease

8. Treatment and Guidelines

9. Epidemiology and Patient Population

10. Autosomal Dominant Polycystic Kidney Disease Patient Journey

11. Marketed Autosomal Dominant Polycystic Kidney Disease Therapies

12. Emerging Autosomal Dominant Polycystic Kidney Disease Therapies

13. Autosomal Dominant Polycystic Kidney Disease Market: 7MM Analysis

14. Autosomal Dominant Polycystic Kidney Disease Market Unmet Needs

15. Autosomal Dominant Polycystic Kidney Disease Market SWOT Analysis

16. KOL Views on Autosomal Dominant Polycystic Kidney Disease

17. Autosomal Dominant Polycystic Kidney Disease Market Access And Reimbursement

18. Bibliography

19. Autosomal Dominant Polycystic Kidney Disease Market Report Methodology

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Shruti Thakur
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/autosomal-dominant-polycystic-kidney-disease-market

Chronic Lymphocytic Leukemia Clinical Trial Pipeline Appears Robust With 55+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s, “Chronic Lymphocytic Leukemia Pipeline Insight 2026” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Chronic Lymphocytic Leukemia (CLL) pipeline landscape. It covers the Chronic Lymphocytic Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Lymphocytic Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight’s comprehensive Chronic Lymphocytic Leukemia Pipeline Report @ Chronic Lymphocytic Leukemia Pipeline Outlook Report

Key Takeaways from the Chronic Lymphocytic Leukemia Pipeline Report

On March 05, 2026- BeOne Medicines initiated a phase 3 study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).
In February 2026- AstraZeneca conducted a Phase IV Study to Investigate Acalabrutinib Monotherapy Compared to Investigator's Choice of Treatment in Adults (> 18 Years) With Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairment.
In February 2026- Genentech Inc. announced a phase II study is to evaluate if adding venetoclax to participants receiving cBTKi for the 1L CLL can achieve deep durable remissions of undetectable measurable residual disease [uMRD < or 10^-4 in peripheral blood (PB)] by end of combination treatment (EOCT) to allow off-treatment period. The acronym BRAVE stands for Btki Responders to Achieve deep remission (or off-treatment periods) with VEnetoclax.
DelveInsight’s Chronic Lymphocytic Leukemia pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Chronic Lymphocytic Leukemia treatment.
The leading Chronic Lymphocytic Leukemia Companies such as Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, and others.
Promising Chronic Lymphocytic Leukemia Therapies such as Obinutuzumab, Rituximab, Chlorambucil, Acalabrutinib, and others.

Access DelveInsight’s in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Chronic Lymphocytic Leukemia Clinical Trials and Studies

Chronic Lymphocytic Leukemia Overview

Chronic lymphocytic leukemia (CLL) is a malignancy of CD5+ B cells that is characterized by the accumulation of small, mature-appearing neoplastic lymphocytes in the blood, bone marrow, and secondary lymphoid tissues, resulting in lymphocytosis, leukemia cell infiltration of the bone marrow, lymphadenopathy, and splenomegaly. The exact etiology of CLL is unknown. Genetic factors, rather than environmental factors, are the most likely cause of CLL. However, few known risk factors for CLL include occupational causes by exposure to certain chemicals, radiation exposure, and tobacco users. Reports of farmers working around rubber manufacturing industries and workers with exposure to benzene and heavy solvents have shown an increased risk of CLL.

Chronic Lymphocytic Leukemia Emerging Drugs Profile

Pirtobrutinib: Loxo Oncology

Pirtobrutinib is an investigational, oral, highly-selective, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor. BTK plays a key role in the B-cell antigen receptor, signaling pathway, which is required for the development, activation and survival of normal white blood cells, known as B-cells, and malignant B-cells. Pirtobrutinib was designed to reversibly bind BTK, deliver consistently high target coverage regardless of BTK turnover rate, preserve activity in the presence of the C481 acquired resistance mutations, and avoid off-target kinases that have complicated the development of both covalent and investigational non-covalent BTK inhibitors. The drug is currently being evaluated in Phase III stage of development for the treatment of chronic lymphocytic leukemia.

Cirmtuzumab: Oncternal Therapeutics

Cirmtuzumab is a first-in-class humanized monoclonal antibody that binds with high affinity to a biologically important epitope on ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1). ROR1 is a type 1 transmembrane protein, essential for fetal development that is expressed on the plasma membrane with an extracellular domain that is essential for ligand binding and signal transduction. Cirmtuzumab binds to many different types of cancer cells but does not recognize most normal adult tissues. Cirmtuzumab was developed at the University of California in San Diego based on the pioneering scientific research of Thomas Kipps, MD, Ph.D., and his colleagues at the Moores Cancer Center. Oncternal holds an exclusive worldwide license to develop and commercialize antibodies recognizing ROR1. The development of cirmtuzumab has been supported by the California Institute for Regenerative Medicine (CIRM), in recognition of the role of ROR1 in conferring stem cell-like properties to the cancer cells that express it. A Phase II clinical trial is evaluating Cirmtuzumab to treat CLL.

MS-553: MingSight Pharmaceuticals

MS-553 is a potent, highly selective, oral, non-covalent inhibitor of PKCβ, a signaling molecule immediately downstream of BTK and PLCγ2 in the B-cell receptor (BCR) pathway. As PKCβ is downstream of both BTK and PLCγ2, it has the potential to treat acquired BTK resistance mutations in either protein, a feature absent from many second-generation BTK inhibitors. In the preliminary results, MS-553 was generally well tolerated, with initial anti-tumor activity seen in the heavily pretreated population. Potent to full inhibition of PKCβ signaling over 24 hours of exposure has been demonstrated. Additional dosing of patients will be completed to further assess MS-553 efficacy in patients with acquired resistance mutations in BTK and PLCG2. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of CLL.

NX-2127: Nurix Therapeutics

NX-2127 is an oral small molecule that combines the activity of a targeted BTK degrader with the cereblon immunomodulatory activity of an IKZF degrader. Cereblon immunomodulatory drugs that induce degradation are IKZF1 and IKZF3. Preclinical data support the activity of NX-2127 in tumor models harboring either wild-type BTK or BTK with mutations conferring clinical resistance to FDA-approved agents. Studies in non-human primates confirm potent BTK degradation with once-daily oral dosing. NX-2127 is being tested in an ongoing Phase I trial for patients with chronic lymphocytic leukemia who have failed prior treatments.

NX-5948: Nurix Therapeutics

NX-5948 is an oral small molecule degrader of BTK. Preclinical data support the activity of NX-5948 in tumor models harboring either wild-type BTK or BTK with mutations conferring clinical resistance to leading FDA approved agents. NX-5948 lacks cereblon immunomodulatory activity and has demonstrated the ability to cross the blood-brain barrier in animal models. NX-5948 has also demonstrated activity in animal models of autoimmune disease. The drug is currently being evaluated in the Phase I stage of development for the treatment of chronic lymphocytic leukemia.

The Chronic Lymphocytic Leukemia Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Lymphocytic Leukemia with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Lymphocytic Leukemia Treatment.
Chronic Lymphocytic Leukemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Chronic Lymphocytic Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Lymphocytic Leukemia market

Explore groundbreaking therapies and clinical trials in the Chronic Lymphocytic Leukemia Pipeline @ New Chronic Lymphocytic Leukemia Drugs

Chronic Lymphocytic Leukemia Companies

Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, and others.

Chronic lymphocytic leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Chronic Lymphocytic Leukemia Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download DelveInsight’s latest report to gain strategic insights into upcoming therapies and key developments @ Chronic Lymphocytic Leukemia Market Drivers and Barriers, and Future Perspectives

Scope of the Chronic Lymphocytic Leukemia Pipeline Report

Coverage- Global
Chronic Lymphocytic Leukemia Companies- Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, and others.
Chronic Lymphocytic Leukemia Therapies- Obinutuzumab, Rituximab, Chlorambucil, Acalabrutinib, and others.
Chronic Lymphocytic Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Chronic Lymphocytic Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Chronic Lymphocytic Leukemia drug development? @ Chronic Lymphocytic Leukemia Emerging Drugs and Major Companies

Table of Contents

Introduction
Executive Summary
Chronic lymphocytic leukemia: Overview
Pipeline Therapeutics
Therapeutic Assessment
Chronic lymphocytic leukemia– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Pirtobrutinib: Loxo Oncology
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Cirmtuzumab: Oncternal Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
NX-2127: Nurix Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Chronic lymphocytic leukemia Key Companies
Chronic lymphocytic leukemia Key Products
Chronic lymphocytic leukemia- Unmet Needs
Chronic lymphocytic leukemia- Market Drivers and Barriers
Chronic lymphocytic leukemia- Future Perspectives and Conclusion
Chronic lymphocytic leukemia Analyst Views
Chronic lymphocytic leukemia Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-pipeline-insight

Bile Duct Cancer Clinical Trial Pipeline Accelerates as 50+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Bile Duct Cancer Pipeline Insights 2026” report provides comprehensive insights about 50+ companies and 60+ pipeline drugs in Bile Duct Cancer pipeline landscape. It covers the Bile Duct Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bile Duct Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download DelveInsight’s comprehensive Bile Duct Cancer Pipeline Drugs Report @ Bile Duct Cancer Pipeline Outlook Report

Key Takeaways from the Bile Duct Cancer Pipeline Report

On March 05, 2026- Endeavor Biomedicines Inc. conducted a phase 2 study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF) mutations in the Patched-1 (PTCH1) gene. Stage 1 of this study will enroll approximately 44 patients randomized between two dose levels. As appropriate, Stage 2 of the study will expand enrollment based on the results of Stage 1.
On March 04, 2026- AstraZeneca announced a Phase III, randomized, double-blind, placebo-controlled, multicenter, global study to assess the efficacy and tolerability of rilvegostomig compared to placebo in combination with investigator's choice of chemotherapy (capecitabine, S-1(tegafur/ gimeracil/ oteracil) or gemcitabine/cisplatin) as adjuvant treatment in participants with BTC after resection with curative intent. This study will be conducted in patients with BTC who are at risk of recurrence after resection with curative intent.
On March 02, 2026- Eisai Co. Ltd initiated a phase 2 study is to assess the objective response rate (ORR) of E7090 by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 based on independent imaging review (IIR) in participants with unresectable cholangiocarcinoma with FGFR2 gene fusion who failed gemcitabine-based combination chemotherapy.
DelveInsight’s Bile Duct Cancer pipeline report depicts a robust space with 50+ active players working to develop 60+ pipeline therapies for Bile Duct Cancer treatment.
The leading Bile Duct Cancer Companies such as Wellmarker Bio, Virogin Biotech Canada, TransThera Sciences, Tango Therapeutics, Taiho Oncology, Tyra Biosciences, Anheart Therapeutics, Nuvalent, Array BioPharma, InnoCare Pharma, NextPoint Therapeutics, and others.
Promising Bile Duct Cancer Therapies such as GNS561 + Trametinib, Tinengotinib 8 mg, Durvalumab, E7090, Pemigatinib, Gemcitabine, Cisplatin, Ivosidenib, and others.

Access DelveInsight’s in-depth Bile Duct Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Bile Duct Cancer Clinical Trials and Studies

Bile Duct Cancer Overview

Cholangiocarcinoma is an aggressive malignancy that originates from the biliary epithelium, both inside and outside the liver. Certain preexisting conditions and diseases can increase the risk of developing cholangiocarcinoma. This neoplasm is difficult to diagnose because obtaining a tissue sample for confirmation is not always possible. Unfortunately, cholangiocarcinoma is often locally invasive or metastatic by the time it is detected. While surgery is the only cure, radiation, chemotherapy, and targeted therapy can also be used in conjunction with surgery. It is classified by anatomical origin as intrahepatic cholangiocarcinoma (iCCA) or extrahepatic cholangiocarcinoma (eCCA); eCCA is subdivided into perihilar cholangiocarcinoma (pCCA) and distal cholangiocarcinoma (dCCA). More than 95% of cholangiocarcinomas are adenocarcinomas.

Bile Duct Cancer Emerging Drugs Profile

TT-00420: TransThera Biosciences

TT-00420 is an innovative, global phase III stage spectrum-selective kinase inhibitor that exerts antitumor effects by targeting tumor cells and improving the tumor microenvironment. Ongoing clinical trials in the US and China have revealed the potential of TT-00420 to be efficacious in various solid tumors. It was granted the Orphan-Drug Designation and Fast Track Designation by the FDA for the treatment of CCA. In July 2023, TT-00420 was granted the Breakthrough Therapy Designation (BTD) by NMPA in China.

VG161: Virogin Biotech

VG161, Virogin’s pioneering oncolytic virus built on the company’s proprietary SynerlyticTM Platform, is an attenuated herpes simplex virus type 1 (HSV-1) armed with multiple payloads of IL12 & IL15/IL15Ra and a unique PD-L1 blocking peptide. The neurovirulence of wild-type HSV-1 is mitigated by the deletion of ICP 34.5 gene. These payloads can synergistically stimulate both innate and adaptive anti-tumor immunity in the tumor microenvironment. VG161 has been confirmed to be safe and effective in many tumor xenograft mouse models and in GLP toxicity studies preclinically. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Cholangiocarcinoma.

NXP800: Nuvectis Pharma

NXP800 is an oral, small molecule, potentially first-in-class GCN2 kinase activator. NXP800 is also being evaluated in an investigator-initiated study conducted in collaboration with the Mayo Clinic for the treatment of cholangiocarcinoma, an indication for which the FDA granted NXP800 Orphan Drug Designation. The NXP800 development program in platinum-resistant, ARID1a-mutated ovarian cancer was granted Fast Track Designation by the FDA. NXP800 completed a Phase 1a dose-escalation study in the first half of 2023. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Cholangiocarcinoma.

The Bile Duct Cancer pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Bile Duct Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bile Duct Cancer Treatment.
Bile Duct Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Bile Duct Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bile Duct Cancer market.

Get a detailed analysis of the latest innovations in the Bile Duct Cancer pipeline. Explore DelveInsight’s expert-driven report today! @ Bile Duct Cancer Unmet Needs

Bile Duct Cancer Companies

Wellmarker Bio, Virogin Biotech Canada, TransThera Sciences, Tango Therapeutics, Taiho Oncology, Tyra Biosciences, Anheart Therapeutics, Nuvalent, Array BioPharma, InnoCare Pharma, NextPoint Therapeutics, and others.

Bile Duct Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Bile Duct Cancer Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming Bile Duct Cancer Therapies and Developments @ Bile Duct Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Bile Duct Cancer Pipeline Report

Coverage- Global
Bile Duct Cancer Companies- Wellmarker Bio, Virogin Biotech Canada, TransThera Sciences, Tango Therapeutics, Taiho Oncology, Tyra Biosciences, Anheart Therapeutics, Nuvalent, Array BioPharma, InnoCare Pharma, NextPoint Therapeutics, and others.
Bile Duct Cancer Therapies- GNS561 + Trametinib, Tinengotinib 8 mg, Durvalumab, E7090, Pemigatinib, Gemcitabine, Cisplatin, Ivosidenib, and others.
Bile Duct Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Bile Duct Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find out in DelveInsight’s exclusive Bile Duct Cancer Pipeline Report—access it now! @ Bile Duct Cancer Emerging Drugs and Major Companies

Table of Content

Introduction
Executive Summary
Bile Duct Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Bile Duct Cancer– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
TT-00420: TransThera Biosciences
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
VG161: Virogin Biotech
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
NXP800: Nuvectis Pharma
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Bile Duct Cancer Key Companies
Bile Duct Cancer Key Products
Bile Duct Cancer- Unmet Needs
Bile Duct Cancer- Market Drivers and Barriers
Bile Duct Cancer- Future Perspectives and Conclusion
Bile Duct Cancer Analyst Views
Bile Duct Cancer Key Companies
Appendix

About Us

PTA Balloon Catheter Market size to Reach USD 4.96 Billion by 2031 as Minimally Invasive Vascular Procedures Expand Worldwide

Mordor Intelligence has published a new report on the pta balloon catheter market, offering a comprehensive analysis of trends, growth drivers, and future projections.

Introduction

According to Mordor Intelligence, the pta balloon catheter market size is estimated at USD 3.10 billion in 2025 and is projected to reach USD 3.35 billion in 2026, eventually expanding to USD 4.96 billion by 2031. The pta balloon catheter market forecast indicates steady expansion driven by the rising global burden of vascular diseases and wider use of minimally invasive procedures in cardiovascular care.

A pta balloon catheter is used in percutaneous transluminal angioplasty procedures to widen narrowed or blocked blood vessels. The device contains a balloon at its tip that is inflated briefly to restore blood flow before being deflated and removed. As hospitals and physicians increasingly prefer minimally invasive treatment options, the pta balloon catheter industry continues to see higher adoption across vascular interventions.

PTA Balloon Catheter Market Trends Shaping the Industry

Rising Burden of Cardiovascular and Peripheral Artery Diseases

One of the most important pta balloon catheter market trends is the growing number of patients diagnosed with coronary artery disease and peripheral vascular disease. These conditions often require angioplasty procedures to restore blood flow in affected arteries.

Increasing Use of Drug-Coated Balloon Technologies

Another notable trend influencing the pta balloon catheter market share is the increasing use of drug-coated balloons in angioplasty procedures. These devices release medication directly into the arterial wall during treatment, helping reduce the risk of restenosis.

Integration of Precision-Guided Balloon Selection Systems

The use of precision-guided tools for vessel sizing is also influencing pta balloon catheter market trends. Accurate vessel measurement helps physicians choose appropriate balloon sizes for angioplasty procedures, improving treatment accuracy and procedural efficiency.

Check out more details and stay updated with the latest industry trends, including the Japanese version for localized insights: https://www.mordorintelligence.com/ja/industry-reports/global-pta-balloon-catheter-market?utm_source=abnewswire

PTA Balloon Catheter Market Segmentation

By Material Type

Polyurethane

Nylon

Pebax and other advanced polymers

By Coating Type

Plain non-coated balloons

Drug-coated balloons with paclitaxel

Specialty hydrophilic coatings

By Compliance Level

Compliant balloons

Semi-compliant balloons

Non-compliant balloons

By Application

Coronary artery disease treatment

Peripheral vascular disease treatment

Renal artery disease procedures

Neurovascular disease procedures

AV fistula stenosis treatment

By End User

Hospitals

Ambulatory surgical centers

Other healthcare facilities

By Geography

North America

Europe

Asia-Pacific

Middle East and Africa

South America

PTA Balloon Catheter Market Competitive Landscape and Key Players

Recent industry activity also shows consolidation among medical device companies as they seek stronger global distribution networks and broader product portfolios. Such strategies influence the competitive dynamics of the pta balloon catheter market share among leading manufacturers.

Key Players in the PTA Balloon Catheter Market

Medtronic plc

Terumo Corporation

Boston Scientific Corporation

Natec Medical

Cardinal Health

Conclusion

The global pta balloon catheter market is expected to continue expanding as cardiovascular diseases remain a major health concern worldwide. The increasing use of minimally invasive vascular procedures is strengthening the demand for angioplasty devices, which directly supports ongoing pta balloon catheter market growth.

Growing adoption of drug-coated balloons, wider clinical acceptance of angioplasty procedures, and continuous improvements in catheter technology are influencing the future direction of the pta balloon catheter industry. Healthcare providers are also focusing on improving treatment outcomes while minimizing patient recovery time, further supporting the pta balloon catheter market forecast.

Industry Related Reports

Angioplasty Balloons Market:

The angioplasty balloons market is segmented by product type, application, end user, and geography, with growth driven by the increasing prevalence of cardiovascular diseases and rising adoption of minimally invasive interventional procedures.

Get more insights: https://www.mordorintelligence.com/industry-reports/angioplasty-balloons-market?utm_source=abnewswire

Gastric Balloons Market size:

The gastric balloons market is projected to grow from USD 87.99 million in 2026 to USD 164.27 million by 2031 at a CAGR of 13.31%, driven by rising obesity rates and increasing demand for non-surgical weight loss treatments.

Get more insights: https://www.mordorintelligence.com/industry-reports/gastric-balloons-market?utm_source=abnewswire

Intragastric Balloon Market share:

The intragastric balloon market is expected to register a CAGR of 9.1% during the forecast period, supported by growing awareness of obesity management solutions and increasing preference for minimally invasive bariatric procedures.

Get more insights: https://www.mordorintelligence.com/industry-reports/intragastric-balloon-market?utm_source=abnewswire

About Mordor Intelligence:

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

For any inquiries or to access the full report, please contact:

media@mordorintelligence.com https://www.mordorintelligence.com/

Media Contact
Company Name: Mordor Intelligence Private Limited
Contact Person: Jignesh Thakkar
Email:Send Email
Phone: +1 617-765-2493
Address:11th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli
City: Hyderabad
State: Telangana 500008
Country: India
Website: https://www.mordorintelligence.com/

CNC Machines Market to Reach USD 104.76 Billion by 2031 as Digital Manufacturing and Precision Engineering Support Market

CNC Machines Market Size & Trends | Mordor Intelligence

Mordor Intelligence has published a new report on the CNC machines market, offering a comprehensive analysis of trends, growth drivers, and future projections

CNC Machines Market Overview

According to Mordor Intelligence, the CNC machines market size is estimated at USD 79.14 billion in 2026, rising from USD 74.82 billion in 2025, and the market forecast indicates the market will reach USD 104.76 billion by 2031, growing at a CAGR of 5.78% during 2026–2031. The expansion reflects strong demand for digitally enabled manufacturing systems across sectors such as automotive, aerospace, electronics, and industrial equipment production.

A key factor behind CNC machines market growth is the increasing need for high-precision machining in advanced manufacturing programs. Electric-vehicle components, aerospace structures, and semiconductor equipment require tight tolerance levels and consistent machining accuracy. As a result, manufacturers continue to adopt CNC platforms that combine hardware, software, and digital monitoring tools to improve machining efficiency.

CNC Machines Market Growth Drivers

Growing Adoption of Digital Manufacturing Systems

One of the major CNC machines market trends is the adoption of digitally connected machining environments. Manufacturers are integrating CNC machines with factory management software, digital twin platforms, and predictive maintenance tools. These systems help production teams monitor machine performance, detect faults earlier, and optimize machining processes. Digital integration also improves operational transparency. Machine data collected from sensors allows manufacturers to analyze cycle times, cutting parameters, and machine utilization levels. These insights enable better process planning and help factories reduce scrap levels and improve product consistency. As more facilities move toward connected production environments, demand for advanced CNC platforms continues to rise across the industry.

Rising Demand from Electric Vehicle and Aerospace Manufacturing

The rapid growth of electric mobility and aerospace manufacturing is another important driver of the market. Electric vehicles require specialized components such as battery housings, lightweight structural parts, and precision motor assemblies that demand accurate machining processes. Similarly, aerospace manufacturers rely heavily on multi-axis CNC machines to produce complex aircraft components. Precision machining is necessary to maintain structural safety and regulatory compliance in aviation programs. As these sectors expand production, the need for advanced machining technologies supports steady CNC machines market growth.

Expansion of Predictive Maintenance and Service Models

Another important market trend involves the growing use of predictive maintenance services. Equipment suppliers are increasingly offering service packages that monitor machine performance and identify maintenance requirements before failures occur. These service-based business models help manufacturers extend machine life and maintain continuous production. Predictive analytics platforms also allow suppliers to collect operational data from installed machines, helping them provide performance recommendations and optimize machining processes. This shift toward service-oriented solutions is gradually influencing the competitive landscape of the CNC machines industry.

Check out more details and stay updated with the latest industry trends, including the Japanese version for localized insights: https://www.mordorintelligence.com/industry-reports/cnc-machines-market?utm_source=abnewswire

CNC Machines Market Segmentation

By Machine Type

CNC lathes

CNC milling machines

CNC laser cutting machines

CNC plasma cutters

CNC EDM machines

CNC grinding machines

CNC drilling and tapping centers

By Axis Type

Three-axis machines

Four-axis machines

Five-axis machines

Six-axis and higher

By End-User Industry

Automotive manufacturing

Aerospace and defense production

Electronics and semiconductor equipment manufacturing

Medical device production

Construction and heavy machinery manufacturing

Power and energy equipment production

Shipbuilding operations

General manufacturing and job-shop machining

By Geography

North America

South America

Europe

Asia-Pacific

Middle East and Africa

Explore Our Full Library of Metal Working and Fabrication Research Reports: https://www.mordorintelligence.com/market-analysis/metal-working-and-fabrication?utm_source=abnewswire

CNC Machines Market Key Players

FANUC Corporation

DMG Mori Co. Ltd

Haas Automation Inc.

Okuma Corporation

Mitsubishi Electric Corporation

Conclusion

The long-term CNC machines market forecast remains positive as global manufacturing continues to adopt automation and precision machining technologies. Industries such as electric mobility, aerospace manufacturing, and electronics production require advanced machining capabilities, ensuring sustained demand for CNC systems. Digital manufacturing strategies will play an important role in shaping the future of the industry. As factories integrate machine monitoring platforms, predictive maintenance tools, and digital simulation software, CNC machines will increasingly operate as connected production assets rather than standalone equipment.

Supply-chain adjustments and regional manufacturing investments are also expected to support market growth in the coming years. Companies are strengthening domestic machining capacity to improve supply reliability and reduce production risks. Overall, the CNC machines market size will continue to expand as manufacturers prioritize efficiency, precision, and production flexibility. Equipment suppliers that combine reliable hardware, intelligent software systems, and strong service support are likely to maintain a competitive position in the evolving industry.

For more insights on the CNC machines market, please visit the Mordor Intelligence page: https://www.mordorintelligence.com/industry-reports/cnc-machines-market?utm_source=abnewswire

Industry Related Reports:

Machining Centers Market

The Machining Centers Market reached USD 36.64 billion in 2025 and is projected to grow to USD 47.30 billion by 2030, registering a CAGR of 5.24% during the forecast period. The growth is primarily driven by rising automation in manufacturing, increasing demand from automotive and aerospace industries, and the growing adoption of advanced CNC machining technologies to improve production efficiency and precision.

Vertical Milling Machine Market Size

The Vertical Milling Machine Market stands at USD 13.78 billion in 2025 and is expected to reach USD 16.06 billion by 2030, reflecting a CAGR of 3.11%. Market growth is supported by expanding manufacturing activities, rising demand for precision machining in metalworking industries, and increasing investments in industrial machinery across emerging economies.

Get more insights: https://www.mordorintelligence.com/industry-reports/vertical-milling-machine-market?utm_source=abnewswire

Precision Turned Product Manufacturing Market Share

The Precision Turned Product Manufacturing Market is projected to grow from USD 121.05 billion in 2025 and USD 128.39 billion in 2026 to USD 172.31 billion by 2031, registering a CAGR of 6.06% from 2026 to 2031. The market is driven by increasing demand for high-precision components in automotive, aerospace, medical devices, and electronics industries, along with advancements in automated machining technologies.

Get more insights: https://www.mordorintelligence.com/industry-reports/precision-turned-product-manufacturing-market?utm_source=abnewswire

About Mordor Intelligence:

For any inquiries or to access the full report, please contact:

media@mordorintelligence.com https://www.mordorintelligence.com/

Mordor Intelligence, 11th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli, Hyderabad, Telangana – 500032, India

Media Contact
Company Name: Mordor Intelligence
Contact Person: Jignesh Thakkar
Email:Send Email
Phone: +1 617-765-2493
Address:11th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli media@mordorintelligence.com
City: Hyderabad
State: Telangana 500008
Country: India
Website: https://www.mordorintelligence.com/

Lymphedema Treatment Market Expected to Reach USD 1.59 Billion by 2031 Driven by Compression Therapy Adoption and Expanding Cancer Survivorship

Mordor Intelligence has published a new report on the lymphedema treatment market, offering a comprehensive analysis of trends, growth drivers, and future projections.

Introduction

According to Mordor Intelligence, the lymphedema treatment market size is projected to grow from USD 0.95 billion in 2025 to USD 1.03 billion in 2026, and it is expected to reach USD 1.59 billion by 2031, reflecting consistent lymphedema treatment market growth during the forecast period.

This growth in the lymphedema treatment industry is closely linked to the rising number of cancer survivors and improved screening programs. Many patients develop secondary lymphedema after surgeries related to breast cancer, prostate cancer, melanoma, and gynecologic cancers. As survival rates improve, long-term care for lymphatic complications becomes more important, supporting sustained demand in the lymphedema treatment market forecast.

Lymphedema Treatment Market Trends

Rising Prevalence of Cancer-Related Lymphedema

One of the most influential lymphedema treatment market trends is the increasing number of patients who develop lymphatic complications after cancer treatment. Surgical removal of lymph nodes and radiation therapy often affect the lymphatic system, leading to swelling in the arms or legs.

Growing Adoption of Compression Therapy Devices

Compression therapy remains a core treatment approach and continues to play a central role in lymphedema treatment market growth. New compression systems are designed to be lighter, more portable, and easier for patients to use at home.

Expansion of Patient Education and Advocacy Programs

Patient education initiatives are playing an important role in shaping the lymphedema treatment market trends. Advocacy groups and medical organizations are promoting awareness of lymphatic diseases and encouraging early diagnosis.

Lymphedema Treatment Market Segmentation

By Treatment Type

Compression Therapy

Surgery

Laser Therapy

Pharmacologic Therapy

Multi-modal Home Therapy Devices

Other Treatment Types

By Type

Secondary Lymphedema

Primary Lymphedema

By Affected Area

Lower Extremity

Upper Extremity

Genitalia

By End User

Hospitals

Specialty Clinics

Ambulatory Surgical Centers

Homecare Settings

Other End Users

By Geography

North America

Europe

Asia Pacific

Middle East and Africa

South America

Competitive Landscape in the Lymphedema Treatment Industry

The competitive environment within the lymphedema treatment industry includes established medical device manufacturers as well as emerging technology companies developing connected therapy systems. Companies are focusing on improving compression therapy products, enhancing patient comfort, and integrating digital monitoring tools.

Key companies operating in the lymphedema treatment industry include:

Tactile Medical

medi GmbH & Co. KG

3M Company

SIGVARIS GROUP

Huntleigh Healthcare

Conclusion

The future outlook for the lymphedema treatment market remains positive as healthcare systems increase their focus on chronic disease management and post-cancer care. Growing awareness, improved diagnostic tools, and structured patient monitoring programs are encouraging earlier treatment interventions.

As healthcare providers continue to emphasize long-term care for lymphatic disorders, the lymphedema treatment market growth is expected to remain steady. Continued collaboration between device manufacturers, healthcare professionals, and patient organizations will play a key role in shaping the future direction of the lymphedema treatment market size, ensuring better outcomes for patients worldwide.

Industry Related Reports

Biosimilars Market:

The biosimilars market is segmented by product class including monoclonal antibodies, recombinant hormones, immunomodulators, anti-inflammatory agents, and others, and by applications such as blood disorders, growth hormonal deficiency, chronic and autoimmune disorders, and oncology across regions including North America, Europe, Asia-Pacific, the Middle East and Africa, and South America.

Get more insights: https://www.mordorintelligence.com/industry-reports/global-biosimilars-market-industry?utm_source=abnewswire

Preventive Vaccines Market size:

The preventive vaccines market is estimated at USD 79.52 billion in 2026 and is projected to reach USD 103.73 billion by 2031, growing at a CAGR of 5.46% during 2026–2031, driven by increasing immunization programs and rising awareness of disease prevention.

Get more insights: https://www.mordorintelligence.com/industry-reports/preventive-vaccines-market?utm_source=abnewswire

Ayurveda Stomach Care Market share:

The ayurveda stomach care market is projected to grow from USD 0.93 billion in 2026 to USD 1.33 billion by 2031 at a CAGR of 7.34%, supported by rising consumer preference for herbal remedies and increasing demand for natural digestive health products.

Get more insights: https://www.mordorintelligence.com/industry-reports/ayurveda-stomach-care-market?utm_source=abnewswire

About Mordor Intelligence:

For any inquiries or to access the full report, please contact:

media@mordorintelligence.com https://www.mordorintelligence.com/